Insights into an abnormally edited RNA molecule may yield new weapons against a hard-to-kill cancer

April 10, 2013, Agency for Science, Technology and Research (A*STAR), Singapore
Unedited miR-376a* promotes aggressive tumor growth (dark red) in a mouse brain tumor model (top), whereas tumor growth (dark red) modulated by the edited form of the same microRNA, differing by a single base, is limited and non-invasive (bottom). Credit: 2013 A*STAR Institute of Bioengineering and Nanotechnology (top); Reproduced from Ref. 1; 2013 Y. Choudhury et al. (bottom)

Diagnosis of the brain cancer glioblastoma multiforme (GBM) is particularly bad news for patients due to limited available medical options and poor outcomes. Even treatments that can eliminate other malignancies, such as chemotherapy and surgery, buy only limited time for GBM patients.

"The disease usually recurs due to extensive invasion of into the normal and therapeutic resistance," explains Shu Wang of the A*STAR Institute of Bioengineering and Nanotechnology in Singapore. "This cancer's highly lethal nature results in a median survival time of around a year for patients with advanced GBM." As scientists hunt for effective treatments, research from Wang and colleagues could offer a useful strategy for fighting this deadly disease.

Rather than producing protein-coding messenger RNAs (mRNAs), some genes encode short 'microRNAs' that regulate other genes by binding target sequences on the mRNAs that they produce. Some microRNAs undergo further enzymatic 'editing', in which certain nucleotides are changed to inosine, and this 'A-to-I' modification can markedly alter a 's target preference. Since previous studies have indicated a link between abnormal mRNA editing and , Wang and co-workers investigated a group of mRNA-encoding genes known as the miR-376 cluster.

One product of this cluster, miR-376a*, typically undergoes A-to-I editing in healthy brain tissue. By analyzing primary tumor tissue as well as glioma-derived cell lines, the researchers determined that many GBM cells instead tend to carry the unedited form of miR-376a*. Importantly, a comparative analysis of patient tumors indicated that excessive levels of unedited miR-376a* are associated with considerably greater tumor volume (see image).

Follow-up studies by the team supported this connection. Relatively non-invasive glioma-derived cells became far more aggressive in culture when forced to express RNAs that mimic unedited miR-376a*; when transplanted into mice, these cells formed large, irregular tumors that soon killed their hosts. By comparison, cells expressing edited miR-376a* were comparatively quiescent, with limited tumor growth. Wang and co-workers also determined that unedited miR-376a* alters expression of a distinct subset of genes relative to its edited counterpart, some of which appear to contribute directly to its harmful effects.

"Introduction of a single base difference by adenosine-to-inosine 'mutation' in miR-376a* affects the selection of its target genes and redirects its function from inhibiting to promoting glioma cell invasion," says Wang. He adds that these results also highlight forced expression of edited miR-376a* as a possible GBM treatment strategy. He and his team are now exploring different delivery mechanisms for such a therapeutic intervention.

Explore further: Identification of a novel target for glioblastoma treatment

More information: Choudhury, Y. et al. Attenuated adenosine-to-inosine editing of microRNA-376a* promotes invasiveness of glioblastoma cells. The Journal of Clinical Investigation 122, 4059–4076 (2012).

Related Stories

Identification of a novel target for glioblastoma treatment

June 18, 2012
(Medical Xpress) -- A recent study from scientists at the Friedrich Miescher Institute for Biomedical Research has identified a novel target for the treatment of malignant brain tumors. The scientists found that the Mer receptor ...

Researchers say one specific microrna promotes tumor growth and cancer spread

April 3, 2013
Researchers at Moffitt Cancer Center have determined that the overexpression of microRNA-155 (miR-155), a short, single strand of ribonucleic acid encoded by the miR-155 host gene, promotes the growth of blood vessels in ...

MicroRNA molecule may serve as biomarker, target for brain metastases in breast cancer patients

February 5, 2013
Researchers have identified two molecules that could potentially serve as biomarkers in predicting brain metastases in patients with breast cancer, according to data published in Cancer Research, a publication of the American ...

Potential new eye tumor treatment discovered

August 5, 2011
New research from a team including several Carnegie scientists demonstrates that a specific small segment of RNA could play a key role in the growth of a type of malignant childhood eye tumor called retinoblastoma. The tumor ...

Genetic switch shuts down lung cancer tumors in mice

October 25, 2012
Yale researchers manipulated a tiny genetic switch and halted growth of aggressive lung cancer tumors in mice and even prevented tumors from forming.

Recommended for you

Researchers identify a protein that keeps metastatic breast cancer cells dormant

January 23, 2018
A study headed by ICREA researcher Roger Gomis at the Institute for Research in Biomedicine (IRB Barcelona) has identified the genes involved in the latent asymptomatic state of breast cancer metastases. The work sheds light ...

Scientists block the siren call of two aggressive cancers

January 23, 2018
Aggressive cancers like glioblastoma and metastatic breast cancer have in common a siren call that beckons the bone marrow to send along whatever the tumors need to survive and thrive.

Boosting cancer therapy with cross-dressed immune cells

January 22, 2018
Researchers at EPFL have created artificial molecules that can help the immune system to recognize and attack cancer tumors. The study is published in Nature Methods.

Workouts may boost life span after breast cancer

January 22, 2018
(HealthDay)—Longer survival after breast cancer may be as simple as staying fit, new research shows.

Cancer patients who tell their life story find more peace, less depression

January 22, 2018
Fifteen years ago, University of Wisconsin–Madison researcher Meg Wise began interviewing cancer patients nearing the end of life about how they were living with their diagnosis. She was surprised to find that many asked ...

Single blood test screens for eight cancer types

January 18, 2018
Johns Hopkins Kimmel Cancer Center researchers developed a single blood test that screens for eight common cancer types and helps identify the location of the cancer.


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.